Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-339P** is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. U6 snRNA is an abundant non-coding RNA essential for the catalytic activity of the spliceosome in pre-mRNA splicing[3][5]. However, as a **pseudogene**, RNU6-339P does not encode a functional RNA and is not transcribed into an active product[1][4]. Unlike functional U6 snRNA, which is critical for gene expression regulation, RNU6-339P is considered a non-functional genomic relic and does not have known biological activity or disease associations. It is not a druggable target, nor is it a therapeutic target, receptor, enzyme, or known biomarker[1]. Pseudogenes like RNU6-339P may in rare instances act as sources of non-coding RNA fragments or have regulatory roles, but there is no evidence of such function for this specific entry[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 339, pseudogene (RNU6-339P).